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The molecular basis for the clinically observed differ-
ences in the skin photosensitizing activity and therapeu-
tic effectiveness of the topically applied and orally ad-
ministered drug trimethylpsoralen (TMP) was investi-
gated. TMP, when tested topically, is a very potent 
photosensitizing and therapeutically effective furocou-
marin in the treatment of psoriasis. When administered 
orally, however, it is significantly less photosensitizing 
and therapeutically a less effective drug than the com-
monly used furocoumarin 8-methoxypsoralen. This de-
creased reactivity of oral TMP is attributable to its poor 
solubility and rapid in vivo metabolic transformation to 
several inact ive (nonphotosensitizing) metabolites, one 
of which is referred to as 4,8-dimethyl,5' -carboxypsor-
a len (DMeCP). 
The supporting evidence has been obtained by: (a) 
isolation of the urinary metabolite DMeCP and subse-
quent comparison of its properties with the synthetically 
prepared DMeCP and its methyl ester; (b) examining 
the dark and photochemical interactions of TMP, 
DMeCP, and DMeCP methyl ester with DNA and deter-
mining their ability to form interstrand cross-links with 
DNA; and (c) studying the inhibition of DNA and RNA 
synthesis in Ehrlich ascites tumor cells and the killing 
of bacteria and T 2 bacteriophages. The structure-activ-
ity relationship of TMP and DMeCP also has been ex-
amined in normal human subjects and in patients with 
psoriasis. The order of topical therapeutic effectiveness 
in terms of ability to clear psoriasis plaques appeared to 
be: TMP > 8-MOP > DMeCP methyl ester > DMeCP. 
The data also suggest the methyl ester of DMeCP to be 
an interesting nonphotosensitizing furocoumarin that 
photoconjugates to DNA better than 8-MOP and is ther-
apeutically effective in psoriasis. 
Certain photochemotherapeutic agents, commonly referred 
to as furocoumarins or psoralens, are used clinically in the 
treatment of various skin diseases, such as psoriasis [1-3], 
mycosis fungoides [4], viti ligo [5), polymorphous photoderma-
titis [6], and eczema [7]. The photobiologic (skin photosensi-
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t ization) and photochemotherapeutic effects of psoralens are 
believed to involve a stable covalent photoconjugation of the 
furocoumarin with DNA of t he target cells [8-11), resulting in 
the formation of cyclobutane addition products with pyrimi -
dines in t he form of single-strand monofunctional adducts and 
interstrand cross-links between two pyrimidines belonging to 
opposite strands of DNA [8-11]. 
Although 8-methoxypsoralens (8-MOP) and t rimethylpsor-
alen (TMP) have been used clinically, both orally and topically, 
for many years , li ttle is known about t he biotransformation, 
the mode of enzymic reactions involved in metabolism, and the 
nature of urina ry metabolites excreted by humans or laboratory 
animals receiving t hese drugs. Recent ly, t he metabolism of 8-
MOP has been examined by a few investigators [12,13], and 
only li ttle attent ion has been paid to t he photoreactivity and 
metabolism ofTMP. T he isolation and identification of a major 
metaboli te referred to as 4,8-dimethyl,5 '-carboxypsoralen 
(DMeCP) from the urine of human volunteers and mice receiv-
ing oral TMP was reported by our laboratories [14,15] (Fig 1) . 
DMeCP was found to be nonphotosensit izing in guinea pig skin 
and human sk in . Both 8-MOP and TMP evoke skin photosen-
sitization in t he form of eryt hema, edema, and hyperpigmen-
tation when the psoralen-treated skin is exposed to UV A radia-
tion. When evaluated topically, TMP is significant ly a more 
potent photosensitizing agent than 8-MOP [5,14,15). W hen 
administered orally, however , 8-MOP is not on ly a more potent 
skin photosensit izing agent t han TMP but is t herapeutically a 
more effective agent in repigmenting vitiligo [5). These were, 
however, anecdotal statements based on clinical jugment made 
in t he course of using high-dose TMP (1.2- 1.8 mg/kg) and low-
dose 8- MOP (0.6 mg/ kg). The cause of t he decreased reactivity 
and poor photosensitizing activity of orally administered TMP 
was not well understood or carefully studied. We have at-
tempted to determine whether t he decreased photoreactivity of 
TMP was t he result of: (a) its poor solubility in water (4.5 mg/ 
100 ml for 8-MOP and 0.5-1.0 mg/100 ml for TMP) , (b) poor 
in vivo absorption and low circulating levels in plasma and 
skin , or (c) rapid biotransformat ion of TMP to relat ively non-
photosensiti zing moieties. To explore t hese possibilities and to 
elucidate t he molecula r basis of differences in the oral vs topical 
photoreactivi ty, we have examined the interactions of TMP, 
DMeCP, and its methyl ester with DNA and studied t heir 
photochemotherapeutic effectiveness in clearing psoriasis. 
MATERIALS AND METHODS 
The isolation of the metabolite DMeCP from the urine of mice 
receiving TMP was ca rried out by the procedures previously reported 
[14,15]. The method for the synthesis of DMeCP and DMeCP methyl 
ester has also been reported [16). Routine procedures were used to 
obtain the melting point, mass spectra, and ['H]NMR (nuclear mag-
netic resonance) spectra of these chemicals. A sample of synthetic 
DMeCP was tr itiated by Amersham International, England, and puri-
fied by means of thin-layer chromatography using silica gel chromato-
plates and ethanol-chloroform (6:4 v/v) as developing solvents. The 
specific radioactivity of DMeCP was 1.16 x 108 dpm/11mol. A tritiated 
sample of the DMeCP methyl ester was obtained by methylation of the 
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F IG 1. Metabolism of TMP in mice and humans. Reactions I , 2, 
and 3 were established in vitro; reactions 4 and 5 are speculative, based 
on observed molecular weights of 260 and 274 of t he two metabolites. 
Products DMeCP and hydroxy DMeCP were isolated from mouse urine 
and human urine. TMeP = 4,5',8-trimethylpsoralen, DMeHyMeP = 
4,8-dimethyl,5' -hydroxymethylpsoralen, DMeCP = 4,8-dimethyl ,5'-
carboxypsoralen. 
DMeCP with [3H]dimethylsulfate [17] ; its specific radioactivity was 
1.92 x 107 dpm/ ttmol. Calf thymus DNA was purchased from t he Sigma 
Chemical Company; its hyperchromicity, as determined according to 
the method of Marmur and Doty [18] was over 40%. All UV spectro-
photometric determinations were carried out with the aid of double-
beam Perkin E lmer spectrophotometers, Models 554 and 360. 
Ultraviolet Light Sources 
Ultraviolet irradiations involving in vitro experiments of photocon -
jugation of psoralens to DNA, E hrlich asc ites and bacterial cells, and 
T2 bacte riophages were carried out with a Philips HPW 125 high-
pressure mercury lamp equipped with a P hilips filter that t ransmitted 
over 90% of the emitted radiation at 365 nm. The irradiation dose [19] 
was in general 2.9 X 10'6 quanta for a 2-ml sample in the photobinding 
determinations and 2.03 x 1016 quanta per 5-ml sample in biologic 
experiments involving DNA and RNA synthesis, bacterial cells, and 
inactivation of viruses. When different UV exposures and conditions 
have been used (e.g., exposure of human skin or guinea pig skin), the 
irradiance has been expressed in J /cm2 and the fluence was measured 
in mw/cm2 with the aid of an International Light Radiometer, Model 
IL 700, equipped with a cosine-corrected, precalibrated UVA detector 
manufactured by the Internationa l Light Company, Newburyport, 
Massachusetts. The UV A irradiation system used in t hese studies was 
comprised a horizontal planar array of 6 4-foot-long fluorescent tubes 
for guinea pig studies or 50 4 foo t- long fluorescent tubes for human 
studies that emitted 320- 400 nm radiation (GTE Sylvania Lighting 
Products, FR40T12, PUV A lamps) . 
Equilibrium Dialysis and Solubility Experiments 
For establishing the extent of noncovalent molecular complex for -
mation (or hydrogen bonding) between DMeCP and DNA in the dark, 
equilibrium dialysis experiments in duplicate runs were carried out in 
cylindrical cells as desc ribed previously [8,20]. In addition, solubility 
experiments were carried out to determine the noncovalent, dark 
complex formation between the psoralen derivative and DNA. Small 
amounts (""0.5 mg) of the labeled DMeCP methyl ester were suspended 
in 8 ml of water or in the same volume of aqueous solution of DNA 
(0.025, 0.050, and 0.075%) containing 5 mM NaCI. The suspensions 
were shaken for 4 h in a thermostatica lly controlled bath at 25"C and 
then centrifuged at 8000 rpm (7600 g) for 1 h in a refrigerated Sorvall 
cent rifuge equipped with SS-24 rotor . The radioactivity of supernatant 
fractions was cou nted to determine t he amount of the dissolved psor-
alen derivative. 
Photobinding Experiments and Determination of Cross-Links of 
Psoralen in DNA 
Comparative experiments for eva luating the photobinding capacity 
and the cross- linking ability of TMP and of DMeCP and its methyl 
ester were performed by procedures previously reported [8,20] and 
included irradiation of an aqueous solu tion of double-stranded ca lf 
thymus DNA containing trit iated TMP, DMeCP, or DMeCP methyl 
ester (DNAP:compound ratio equal to 75). The extent of psora len-
DNA cross- linking was determined by evaluating the renaturation 
capacity of cross-linked DNA afte r heat denaturation [8,20- 22]. The 
irradiated and nonirradiated DNA solu t ions, after heat denaturation 
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followed by rapid cooling in ice, were chromatographed on a hydrox-
ylapatite Bio-gel type column (0.7 X 4 em, BioRad Laboratories, 
Richmond, California), and the cross- linked and noncross-linked frac -
tions of DNA were separated with a linear gradient of 0.05- 0.3 M 
phosphate buffer, pH 6.98 [8,20,22]. 
Experiments with Ehrlich Ascites Tumor Cells 
The procedure previously used in our laboratories has been adopted 
for these studies with certain modifications [21 ]. Ehrlich ascites tumor 
cells (Lettre strain, Heidelberg) were collected on the 6th to 7th day 
after transplant and diluted up to 2 x 107 cells/ml with Hanks' solu tion 
containing the psoralen derivative (4 ttg/ml). After irradiation, the cells 
(aliquots of 0.5 ml containing 2 x 106 cells) were washed 3 times in ice-
cold Hanks' solution. Their ability to synthesize DNA and RNA was 
examined [21] by incubating the irradiated and the untreated control 
cells for 15 min at 37"C in Hanks' solution in the presence of 1 ttCi 
ml- ' of (3H]thymidine or [aH ]uridine. The DNA and RNA contents 
were determined by the diphenylamine and orcinol reactions, respec-
tive ly [23,24]. The results, calculated as percentage of the radioactivity 
incorporated into nucleic acids of untreated control ce lls (about 2000 
dpm/llg for DNA and 2400 dpm/ttg for RNA), were submitted to probit 
analysis, and the values were expressed as 50% inhibi tion dose or ID50 • 
Experiments with Bacterial Cells and Viruses 
Escherichia coli B,8, a wild type strain, was used. Cells were grown 
in brain-heart infusion (Difco Laboratories, Detroit, Michigan), col-
lected on Millipore filters (HA WP 02500, 0.45 ttm), and irradiated in 
Hanks' solution containing the furocoumarin (4 llg/ml) in Petri dishes, 
as described above (108 cells/ml; samples of 5 ml) . The surviving 
fraction was determined by studying the colony-formin g capacity of 
the irradiated cells on plates prepared with brain-heart infusion agar 
(Difco Laboratories). Experiments with bacterial viruses were carried 
out using T 2 bacteriophages. Viruses were grown using E. coli B,8 as 
host bacteria in brain-heart infusion broth. Irradiation was performed 
as above by di luting the phage suspension up to 109 virus particles per 
ml with Hanks' solution contai ning 4 ttg/ml of the psora len derivatives. 
Phage titers were then determined using the 2- layer method proposed 
by Adams [25]. 
Experiments with In Vivo Absorption and Excretion of fH}TMP in 
Mice 
The kinetics of absorption and excretion of [aH]TMP were studied 
in 12 albino mice. Each mouse received 213 JLg of TMP dissolved in 
0.25 ml peanut oil. Urine, blood, skin , and feces samples were obtained 
at 2, 4, 6, 8, 12, 24, and 48 h after oral (by gavage) administration of 
t he drug. TMP and its metabolites were extracted from urine and 
analyzed for radioactivity [14] . 
Radioactivity Measurements 
Radioactivity of the labeled psoralens added to Insta-gel (Packard 
Chemicals) was measured in a Packard Model 3375 liquid scin t illation 
spectromete r. Tritium counting ef!iciency of the apparatus was 28-
32%. 
Phototoxicity Assay of TMP Derivatives on Guinea Pig Skin and 
Human Shin 
Nine male and female a lbino guinea pigs (Hartley strain), weighing 
600- 800 g each, were used. The dorsal hair of each animal was clipped 
and epilated 24-48 h before the application of the test solutions. 
Ethanolic solutions of TMP, synthetic DMeCP and its methyl ester, 
and the metabolite DMeCP were applied in varying concentrations 
ranging from 2.5- 1000 ttg/6 cm2 (see footnote in Table !). In 1 of the 
10 test sites, .eac h animal also received topical application of 25 llg 8-
MOP /6 cm2 as a positive control. In oral studies, each test chemical 
was evaluated in at least 3 animals. TMP, 8-MOP, DMeCP, and 
DMeCP methyl ester dissolved in 10% gum acacia were given in 
colloidal form by gavage (dose 0.6- 1.2 mg/kg). The epilated backs of 
the animals were exposed in duplicate sites to 12.0 J/cm2 UVA at 1, 2, 
and 3 h after oral ingestion of the drug; each exposure site was 10 sq 
em (4.0 X 2.5 em). The degree of redness was assessed as stated below. 
To minimize t he discomforts of a severe phototoxic reaction in human 
skin, the concentrations of the applied test chemicals, however, were 
decreased and are shown in Table I. The degree of redness was assessed 
at 24 and 48 h after irradiation. The followin g arbitrari ly selected 
scoring system was used: 
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TABLE I. Photosensitizing and therapeutic effectiveness of the various psoralens studied 
Relative photosensitizing activity in Therapeutic Effectiveness in huma n psoriasisc 
Compound and structure Guinea pigs 
Top ica l 
Topical" Oral• 
Human subjects 
Oral 
T op ica l" Oral' 
4,5' ,8-Trimethylpsoralen 
+++ to ++++ ± to + ++to++++ Excellent ~ H3C~O~O~o (0.6 mg/kg) + to++ (1.2 mg/kg) 
0 to± 
(0.6 mg/kg) 
±to++ 
(1.2 mg/kg) 
Fair to 
moderate 
CH3 
8- Methoxypsoralen 
QQOO +to ++ + to ++ (0.6 mg/kg) ++to++++ (1.2 mg/kg) ± to ++ +to ++ (0.6 mg/kg) ++to++++ (1.2 mg/kg) Good to excellent Good to excellent 
OCH 3 
4,8-Dimethyl , 5' -ca rboxypsoralen 
(DMeCP) 
(a) Urina ry metabolite 
(b) Synt hetic 
Inactive 
Inactive 
Inactive 
Inactive 
Inactive 
Inactive 
Not tested 
Not tested 
Poor 
Poor 
Not tested 
Not tested 
HOOC~O 
CH3 
DMeCP methyl ester Inactive 
"Topical studies 
Inactive Inactive Not tested Fair to 
moderate 
Not tested 
Guinea pigs: Each of t he 9 guinea pigs having 10 test sites, each 2.5 X 2.5 em, received topical application of 2.5- 50 f.lg/6 cm2 of TMP or 8-
MOP and 50- 1000 1•g/6 cm2 of DMeCP or its methyl ester. Thirty to 45 minutes after application each test site was exposed to 12 J fcm2 of 
UV A radiation . 
Human subjects: Six human volunteers received topical application of 1.25, 2.5, and 5.0 f.lg/6 cm2 of TMP, 2.5, 5.0, and 10.0 f.lg/cm2 of 8-MOP; 
a nd 25, 50, and 100 f.l g/cm2 of DMeCP. They were exposed to 6 J jcm2 of UVA radiation. 
" Oral studies 
Guinea pigs: In oral evaluation, 3 guinea pigs per compound received either 0.6 mg/kg or 1.2 mg/kg of TMP, 8-MOP, or DMeCP. (metaboli te 
or synt hetic) by force feeding (gavaging) t he a nimals. One, two, and three hours after ingestion, animals were exposed to 12.0 J /cm2 of UVA 
radiation. 
,. T herapeutic effectiveness in humans 
Top ical the rapy involved application of 50 f.lg/cm2 of TMP or 8-MOP a nd 100 11g/6 cm2 of DMeCP to psoriatic plaques (approximately 7 X 7 
em) 3 t imes per week and UVA exposure of 0.5-5.0 J /cm2 in gradual increments for a total of 15- 20 t herapies. On ly 3 patients were evaluated 
for clearance of psoriatic plaques. Excellent = plaque cleared and improved 95- 100%. Good = 75- 95% cleared and improved. Fair = > 25- 50% 
clea red and improved. Poor = 0- 25 % clea rance. 
0 
± 
+ 
++ 
+++ 
++++ 
No erythema indicating inactive compound 
Questionable erythema indicating minimal or uncertain 
activi ty 
Definite redness (pink ) indicating weakly active com-
pound 
Moderate erythema (pink-red) indicating moderately ac-
t ive compound 
Brick-red erythema with edema indicating strongly active 
compound 
In tense erythema, edema and vesiculation or oozing re-
action indicating ext remely active compound 
Topical Treatment of Psoriatic Plaques 
Each test chemical was evaluated in at least 3 patients with plaque 
type psorias is. Ethanolic solu t ions of t he test compounds were applied 
(8- 10 ltg/cm2) to small plaques (10 X 10 em) 45 min before irradiation . 
Treatments of plaques were init ially based on minimal phototoxic dose 
(MPD), usually in t he range of 0.50 ± 0.25 J /cm2, and subsequent ly on 
clinical judgement of t he dose needed to mainta in a minima l but 
defini te erythema of the treated skin. Treatments were carried out on 
alternate days, 3 times per week for a total of 20 treatments. T he 
clinical improvement or clearance of plaques was evaluated on an 
a rbitra ry scale of 1 to 100% weekly up to 6 weeks of treatment. 
RESULTS 
Absorption and Excretion of TMP in Mice 
Orally administered TMP solubilized in oil was absorbed 
readi ly as can be seen in Fig 2a.. Over 88% of t he administered 
radioactivity dose could be recovered in the urine within 8 h 
and over 90% within 12 h. The dist ribut ion patterns of TMP 
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FtG 2. a, Absorption and excretion of TMP in t he urine and feces 
of mice receiving 213 J.Lg/0.25 ml oral administration of the drug by 
intubation. The curve ._. represents urinary excretion (in nmol) 
of the tritium-labeled metabolites at 2, 4, 8, 12, 24, and 48 h after oral 
administration of [JH]TMP. The cu rve 0 -- - 0 represents percent 
urinary excretion of administered dose of ["H]TMP. Fecal excretion of 
[ 3H]TMP is also shown a nd varied from 5- 10%. b, Distribution pat· 
terns of TMP radioactivity obtained at different time intervals in 
blood, liver, and skin. Each of the test animals received 213 J.Lg TMP 
by oral in tubation. 
radioactivity obtained at different time intervals in blood, liver, 
skin (F ig 2b), and other organs of mice revealed that TMP was 
present in high concentrations at 2- 4 h; the reafter the values 
declined gradually. Radioactivi ty counts observed in the heart, 
lungs, brain , intestines, kidney, spleen, and other tissues are 
not shown in the figure as these tissues contained a small 
amount of radioactivity totaling less than 5% of the admin is-
tered dose. The highest concentration of TMP was obtained at 
2-4 h with maximum values at 2- 2112 h; thereafter, the TMP 
concentration declined gradually. About 5-10% of the unme-
taboli zed TMP was excreted in the feces (Fig 2a). 
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Comparison of the Synthetic DMeCP and the metabolite 
DMeCP 
1. T he synthetically prepared DMeCP and the metabolite 
DMeCP isolated from the urine of mice receiving the drug 
TMP orally revealed a lmost identical absorption spectra with 
major peaks at 220, 260, 266, and 306 nm, and a broad peak at 
330 nm. 
2. Both compounds ex hibited a blue t1uorescence with the 
exc itation maximum at 350 nm and the emission maximum at 
430 nm. 
3. The solubili ty studies revealed that DMeCP was slightly 
soluble in water and easi ly oluble in sodium bicarbonate so-
lution. The solubili ty of DMeCP in decreasing order was 
NaHC0:1 > H~O >ethanol > CHC1,1• 
4. The nuclea r magnetic resonance spectrum (NMR, 80 
MHz) of the synthetic DMeCP in deuterated ch loroform 
(CHCla) was identical to the spectrum already reported for the 
metabolite DMeCP isolated from the urine of mice receiving 
oral TMP [14]. 
Darh Interaction of DMeCP and Its Ester with DNA 
The first indication of the complex formation (noncovalent 
interaction) in the dark between DMeCP or DMeCP methyl 
ester and DNA was obtained by spectrophotometric investiga-
tions. The antic ipated decrease in the absorption value at the 
300-370 nm range as well as a red shift of the "A max could not 
be seen. The absorption spectra obtained with DMeCP in the 
presence and absence of DNA in the 300-370 nm range were 
practically superimposable, thus indicating litt le or no dark 
complex formation between DMeCP and DNA. In contrast, 
TMP has been previously shown to exhibit a very high affini ty 
to DNA and to undergo dark complex formation [26]. 
To verify these findings, additional quantitative in fo rmation 
on the extent of the complex formation of DMeCP and DMeCP 
methyl ester with DNA was obtained. A series of equilibrium 
dia lysis experiments were ca rried out using tritium-labeled 
compounds. The results reported in Table ll indicate that the 
molecula r complex formation between DMeCP and DNA does 
occur but in an extremely reduced form. In the most favorable 
condition (using 2.5 X 10-:J M so lutio n of DNA) , only 7% of the 
DMeCP molecules present in the solution were found to be 
complexed with DNA. The solubili ty of DMeCP methyl ester 
in water and in various solutions of DNA (0.025, 0.050, and 
0.075%) was also examined at 25·c. T he so lubility of DMeCP 
methyl este r expressed as l!g/ml in water (1.88 l!g/ml) was 
dramatically increased upon addition of DNA as follows: 5.63 
l!g/ml in 0.025% DNA, 8.38 l!g/ml in 0.05 % DNA, and 12.ll!g/ 
ml in 0.075% DNA. From these measurements, a rough esti-
mate of the apparent binding constant (K) has been calculated 
[26,27] and was fou nd to be 26,000 M- 1 (per mole). Thus, 
DMeCP methyl ester, in contrast to DMeCP, shows a relatively 
good complex ing abili ty with DNA. 
Covalent Interaction with DNA 
The photobinding capacity of DMeCP and its methyl ester 
to DNA was also compared. The resu lts presented in Fig 3a 
show that DMeCP has a very low capacity to photoconjugate 
with DNA as compared with the parent molecule TMP which 
TABLE II. Results obtained in equilibrium dialysis experiments 
concerning the complex formation between DMeCP a.nd DNA 
DNA so lu tion 
2.50 X 10-3 M 
1.36 X 10- 3 M 
0.55 X 10-" M 
0.14 X 10- 3 M 
oncentration of DMeCP 
In the water sec· 
tion 
1.24 X 10-r. M 
1.25 X 10-r. M 
1.27 X 10- 5 M 
1.29 X 10-" M 
In the DNA -con· 
ta ining section 
1.33 X 10- 5 M 
1.32 X 10- 6 M 
1.30 X 10-5 M 
1.28 X 10-r, M 
Bound t.o DNA 
0.09 X 10-r, M 
0.07 X 10- 5 M 
0.03 X 10- 5 M 
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FIG 3. a a nd b, Photoreaction between DNA and the following 
psoralen derivatives. I = TMP (trimethylpsoralen), 11 = DMeCP (4,8-
dimethyl,5' -carboxypsoralen), III = DMeCP methyl ester, and I V= 8-
MOP (8-methoxypsoralen). Fig 3a represents photoconjugation of 
TMP (!) , DMeCP (II), and DMeCP methyl ester (Ill) with DNA at 
low UV A exposure doses. Fig 3b represents photoconjugation of 
DMeCP (II), DMeCP methyl ester (Ill), and 8-MOP (IV) at high 
UV A exposure doses. Thus t he order of photoconjugation was TMP > 
DMeCP methyl ester > 8-MOP > DMeCP. 
showed very high photoreactivity with DNA. The low conju-
gating abili ty of DMeCP with DNA is significant ly enhanced 
after methylation. The results , shown in Fig 3a., were obtained 
when low irradiation doses were used to demonstrate the high 
and low photoreactivity of TMP and DMeCP with DNA, 
respectively. To ascerta in the extent of photoconjugation of 
DMeCP and its methyl ester at high irradiation doses under 
conditions closer to saturation, photobinding experiments were 
also carried out by delivering more quanta to t he reacting 
so lut ions. The results shown in Fig 3b confirm the above 
findings and indicate very low photoaddition reaction of 
DMeCP and high photoaddition of DMeCP methyl ester (even 
higher than that of 8-MOP) to DNA. 
The resu lts pertaining to the capacity of these substances to 
form interstrand cross- links in DNA, are shown in Fig 4 in 
which the log of t he fraction (percent) of DNA that remained 
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FIG 4. Formation of interstrand cross- links in native DNA after 
photoreaction with the fo llowing psoralen derivatives: I= TMP, II = 
DMeCP, III= DMeCP methyl ester, and IV= 8-MOP. The log of the 
percent of non-naturable fraction of DNA which is inversely correlated 
with the amount of cross- linkages formed in DNA is plotted against 
number of quanta incident. 
in the denatured state has been plotted against the number of 
quanta incident. The results indicate that cross-linking of 
DMeCP with DNA was much lower t han that ofTMP, DMeCP 
methyl ester, and 8-MOP. In fact, DMeCP methyl ester ap-
peared to be a better cross-linking agent to DNA than DMeCP 
and 8-MOP. 
Inhibition of Nucleic Acid Synthesis in Ehrlich Ascites Tumor 
Cells 
Since the photoconjugation of DMeCP methyl ester to DNA 
was found to be higher t han DMeCP and 8-MOP, and poten-
tially th is was an important attribute for the usefulness of the 
compound in photochemotherapy, t he following comparative 
experiments on the inhibition of nucleic acid synthesis in 
bacterial cells and T 2 bacteriophages were carried out with 
DMeCP methyl ester and 8-MOP. The results on DNA syn-
thesis obtained with Ehlrich ascites tumor cells are shown in 
Fig 5. The incorporation of CHJthymidine into DNA was 
strongly inhibited by both compounds. At t he concentration of 
4 !-Lg/ml1 the ID50 values fo r DNA synthesis were 3.4 X 1018 and 
13.8 X 1018 quanta for DMeCP methyl ester and 8-MOP, 
respectively. The IDr,o values for RNA synthesis were 9.7 x 1018 
and 24.9 X 1018 quanta for DMeCP methyl ester and 8-MOP, 
respectively. 
These values indicate that DMeCP methyl ester is about 4 
t imes more active than 8-MOP in inhibiting DNA synthesis 
and about 2.5 times more active in inhibiting RNA synthesis. 
Photosensitization of Bacterial Cells and Viruses 
Tbe survival curves of E. coli B48 cells after irradiation for 
different time intervals in t he presence of 4 1-Lg/ ml of either 
DMeCP methyl ester or 8-MOP are shown in Fig 6. DMeCP 
methyl ester appeared to be very effective in killing E. coli B 4R 
cells and showed an activity about 3 times higher than that of 
8-MOP as determined by comparing the UV radiation dose 
necessary for the two substances to reduce the surviving frac-
tion to 0.37). 
The photosensitization and phage inactivation experiments 
carried out with T 2 bacteriophages yielded practically the same 
results as obtained with bacteria. Also in these experiments, 
DMeCP methyl ester showed an activity about 3 times higher 
than that of 8-MOP. 
Photosensitization Experiments with TMP and Its Metabolites 
in Animals and Human Subjects 
Photosensitizing and photochemotherapeutic activity data of 
DMeCP (synthetic compound and urinary metabolite) , DMeCP 
methyl ester, TMP, and 8-MOP on guinea pig skin and human 
sk in are shown in Table I. As anticipated, TMP and 8-MOP 
when tested top ically in guinea pig skin or human skin were 
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F IG 5. Inhibit ion of DNA synthesis in E hrlich ascites tumor cells 
by irradiation in absence of drugs (UV only, - 0 - 0-) or in the 
presence of DMeCP methyl ester (Ill, - 0 - 0 - ) or 8-MO P (IV, -
6 - 6 - ) . Irrad iated cells were incubated at 37'C in presence of ["H] 
thymidine, and radioactivi ty incorporated in to ac id-insoluble fraction 
was dete rmined. 
potent photosensit izing agents; T MP was about 5-7 t imes more 
effective than 8-MOP in inducing erythema, edema, and micro-
scopically recogn izable cell damage. DMeCP and DMeCP 
methyl ester, when tested topically, were found to be nonpho-
tose nsit izing in both gu inea pig skin and human skin. When 
TMP or 8-MOP were given orally to guinea pigs or human 
subjects, both the drugs were phototox ic, but 8-MOP induced 
a greater degree of skin photosensit ization than TMP. Ora lly 
administe red DMeCP and its methyl este r were tested in guinea 
pigs only; both of the agents were found to be nonphotosensi-
t izing. 
T he therapeut ic effect iveness of TMP, 8-MOP, DMeCP , and 
DMeCP methyl ester was also eva luated in patients with pso-
riasis. When tested topically in t he same individua l, TMP and 
8-MOP we re both effective (T able I) , with t he former more so. 
DMeCP was least effective; its methyl ester showed a defini te 
but moderate activity in clearing psoriatic plaques. Orally ad-
ministered 8-MOP was more effect ive in clea ring psoriasis than 
TMP; t hese observations, albeit derived on a limited number 
of patients, are based on our clinical judgement as determined 
by t he rate of improvement (clearance) of psoriatic plaques 
after 3, 6, 9, 12, and 15 therapy sessions. 
DISCUSSION 
Besides knowing the pharmaco kinetics of drug abso rption or 
epiderma l penetration, t he knowledge of the metabolism and 
biotransformation of a photoactive drug is important in under-
standing t he relationship between its structure, photoreactivity, 
and t herapeut ic activity. In this study, t he clinically obse rved 
differences in the photoreactivity and t herapeutic effectiveness 
of t he topically and orally administe red drug TMP have been 
investigated both by animal experimentation and human use. 
TMP, when topically tested, was found to be a very potent 
photosensit izing agent. When give n ora lly, however, it was a 
weak photosensit izing agent. T his decreased reactivi ty of oral 
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FIG 6. The colony-forming abili ty of E. coli 8 .18 afte r photosensit i-
zation in the p resence of 4,8-dimethyl,5' -ca rboxypsoralen methyl ester 
(JIJ , - 0 - 0-) or 8-MOP (I V, -6-6- ) is plotted against the 
irrad iation dose. E ffect of UV irradiation alone (-0- 0 - ) on the 
surviving fraction in absence of the drug is a lso shown . DMeCP methyl 
este r showed greater inhibi t ion activi ty tha n 8-MOP. 
T MP is attributable to its poor solubili ty (0.5- 1.0 mg/100 ml 
in water for TMP and 4.0- 4.5 mg/100 ml for 8-MOP) and rapid 
in vivo biotransformation to several nonphotosensit izing me-
taboli tes, one of which is DMeCP . 
T o establish the structure-activi ty relationship between 
TMP and DMeCP, this major urinary metabolite of TMP has 
been fur ther cha racterized and ident ified by" synthesis. On the 
basis of various physicochemical propert ies (UV absorpt ion, 
excitation and Huorescent emission spectra, [ 'H]NMR and 
mass spectra, t hin-laye r chromatography, and solubility behav-
ior, etc.), t he synt hetically prepa red DMeCP and t he urina ry 
metaboli te obtained by extraction from urine of patients or 
mice receiving oral TMP have been shown to be ident ica l. 
Experiments with both the synt hetic and urina ry metaboli te 
samples of DMeCP were a lso perfo rmed in parallel to ascertain 
their photosensit izing propert ies on gu inea pig skin and human 
skin . Both the synt hetic and t he metabolite DMeCP were 
nonphotosen.sitizing agents. Even a 10- to 50-fold increment in 
topica l dose of t he metaboli te and an opt imal dose of UV A 
exposure (10- 12 J jcm~) produced no evidence of any erythema, 
edema, or vesiculation reactions as were consistent ly seen with 
low concentrations of TMP (5- 10 p.g/6 em~) or 8-MOP 20- 50 
p.g/6 em~). 
The abso rption and excretion studies of ora lly administered 
T MP in mice suggest t hat TMP, when administered in low 
doses, is reasonably well absorbed and over 88% of t he admin -
istered radioactivity dose can be recovered in the urine within 
8-10 h. 
Because synthetic DMeCP can be prepa red in higher quan-
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tities of greater purity than can be obtained by chemical ex-
traction from urine , the synthetically prepared DMeCP and its 
methyl ester were used for studying their interaction and pho-
toreaction with DNA with a view to explore their potential 
usefulness in the treatment of psoriasis. In the studies per-
formed in vitro, using the tritium-labeled compound, DMeCP 
showed a very low capacity to form a molecular complex with 
DNA and to covalently conjugate to DNA after irradiation. 
The very low interacting capacity between DMeCP and DNA 
is consistent with its structure. The polar DMeCP, containing 
an ionizable carboxylic group and having an electron withdraw-
ing property, appears to undergo a repulsion by the phosphoric 
acid residues of DNA. The increased interaction of methyl ester 
of DMeCP with DNA is due to the altered ionizable character 
of the molecule; DMeCP methyl ester is nonionizable. 
Studies on the formation of interstrand cross-links in DNA 
also provided additional evidence for the high reactivity of 
TMP and the low reactivity of DMeCP or its methyl ester. 
DMeCP formed a small number of cross-links in DNA. The 
methyl ester of DMeCP, however, was a better cross- linking 
agent than DMeCP. The dec reased reactivity of the TMP 
metabolite is further supported by the differences in the degree 
of inhibition of DNA and RNA synthesis in Ehrlich ascites 
tumor cells by DMeCP and its methyl ester. The 4,8-di-
methyl,5 ' -carboxypsoralen methyl ester lacking the ionizable 
character was certainly more effective in killing E. coli B.8 cells 
and more effective in inactivating T 2 bacteriophages than the 
more ionizable DMeCP. Additional evidence in support of this 
hypothesis was obtained by performing topical studies in pa-
tients with psoriasis in which TMP was found to be the most 
effective agent in clearing psoriasis, DMeCP the least effective, 
and methyl ester of DMeCP moderately effective. 
The interpretations of these experimental and clinical find-
ings can be additionally strengthened by our earlier observa-
tions that indicated rapid transformation ofTMP into DMeCP 
and other metabolites by the microsomal enzymes of the liver 
[15]. By contrast, topically applied TMP was not metabolized 
by epidermal homogenates and microsomal fraction of guinea 
pig skin. These findings further suggest that topically applied 
TMP does not get transformed to an inactive form in the 
epidermis but remains as photoreactive TMP capable of caus-
ing photosensitization and cross-linking of DNA. The high 
photosensitizing activity of 8-MOP when given orally is due 
not only to greater absorption and higher solubility than that 
of TMP but is due also to the supporting observations that 8-
MOP under in vivo conditions is metabolized slowly, and the 
metabolites formed in the liver appear to be in the photo reactive 
form (Pathak eta!, unpublished observations). 
These observations suggest that the photobiologic and pho-
tochemotherapeutic activity of psoralens can be modified. One 
of our aims is to develop new compounds which exhibit reduced 
photosensitizing, genetic, and carcinogenic effects and still 
show therapeutic effectiveness in treating skin diseases. Studies 
of this nature thus provide new avenues to obtain better furo-
coumarins than TMP which are nonphotosensitizing yet ther-
apeutically effective in clearing psoriasis. 
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